215 related articles for article (PubMed ID: 26782353)
1. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer.
Miyamoto R; Oda T; Hashimoto S; Kurokawa T; Inagaki Y; Shimomura O; Ohara Y; Yamada K; Akashi Y; Enomoto T; Kishimoto M; Yanagihara H; Kita E; Ohkohchi N
Cancer Sci; 2016 Apr; 107(4):514-20. PubMed ID: 26782353
[TBL] [Abstract][Full Text] [Related]
2. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
Larbouret C; Robert B; Bascoul-Mollevi C; Penault-Llorca F; Ho-Pun-Cheung A; Morisseau S; Navarro-Teulon I; Mach JP; Pèlegrin A; Azria D
Ann Oncol; 2010 Jan; 21(1):98-103. PubMed ID: 19889608
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA
Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
5. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Wild R; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Luo FR; Camuso A; McGlinchey K; Rose WC
Mol Cancer Ther; 2006 Jan; 5(1):104-13. PubMed ID: 16432168
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells.
Duan Y; Yin X; Lai X; Liu C; Nie W; Li D; Xie Z; Li Z; Meng F
Technol Cancer Res Treat; 2020; 19():1533033819895494. PubMed ID: 32336215
[TBL] [Abstract][Full Text] [Related]
10. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts.
Rose WC; Wild R
Clin Cancer Res; 2004 Nov; 10(21):7413-7. PubMed ID: 15534118
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Harada K; Ferdous T; Kobayashi H; Ueyama Y
Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition.
Lin YW; Raj EN; Liao WS; Lin J; Liu KK; Chen TH; Cheng HC; Wang CC; Li LY; Chen C; Chao JI
Sci Rep; 2017 Aug; 7(1):9814. PubMed ID: 28852020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
